tiprankstipranks
Advertisement
Advertisement

DE:78Q Stock Latest News

Company AnnouncementsPhilogen Publishes Shareholders’ Meeting Minutes and Highlights Targeted Cancer-Drug Focus
20d ago
PremiumCompany Announcements
Philogen Maintains Strong Cash Position as Oncology Pipeline Advances on Schedule
29d ago
PremiumCompany Announcements
Philogen Reports April On‑Market Share Purchases by Mediobanca
1M ago
Philogen Approves 2025 Results, €0.70 Dividend and New Share Buyback Mandate
PremiumCompany Announcements
Philogen Approves 2025 Results, €0.70 Dividend and New Share Buyback Mandate
1M ago
Philogen Continues Euronext Milan Share Buyback, Nears 0.9% Treasury Stake
PremiumCompany Announcements
Philogen Continues Euronext Milan Share Buyback, Nears 0.9% Treasury Stake
1M ago
Philogen Details Voting Rights Structure Ahead of April 29 Shareholders’ Meeting
PremiumCompany AnnouncementsPhilogen Details Voting Rights Structure Ahead of April 29 Shareholders’ Meeting
2M ago
Philogen Adds to Treasury Stock as Biotech Group Advances Targeted Cancer Strategy
Premium
Company Announcements
Philogen Adds to Treasury Stock as Biotech Group Advances Targeted Cancer Strategy
2M ago
Philogen Expands Treasury Stock Position as Share Buyback Programme Progresses
Premium
Company Announcements
Philogen Expands Treasury Stock Position as Share Buyback Programme Progresses
2M ago
Philogen Publishes 2025 Financial and Governance Reports Ahead of April 2026 Shareholders’ Meeting
PremiumCompany Announcements
Philogen Publishes 2025 Financial and Governance Reports Ahead of April 2026 Shareholders’ Meeting
2M ago
Philogen Discloses March Share Purchases by Mediobanca on Italian Market
PremiumCompany Announcements
Philogen Discloses March Share Purchases by Mediobanca on Italian Market
2M ago
Philogen Publishes Documentation Ahead of April 2026 Shareholders’ Meeting
PremiumCompany Announcements
Philogen Publishes Documentation Ahead of April 2026 Shareholders’ Meeting
2M ago
Philogen posts record 2025 profit on RayzeBio deal, plans dividend and R&D push
PremiumCompany Announcements
Philogen posts record 2025 profit on RayzeBio deal, plans dividend and R&D push
2M ago
Philogen Expands Treasury Share Buyback, Nears 0.87% of Share Capital Held
PremiumCompany AnnouncementsPhilogen Expands Treasury Share Buyback, Nears 0.87% of Share Capital Held
3M ago
Philogen Adds to Treasury Stock with Ongoing Share Buyback on Euronext Milan
Premium
Company Announcements
Philogen Adds to Treasury Stock with Ongoing Share Buyback on Euronext Milan
3M ago
Philogen Advances New Skin Cancer Trial, Extending Long‑Term Upside Optionality for DE:78Q Investors
Premium
Company Announcements
Philogen Advances New Skin Cancer Trial, Extending Long‑Term Upside Optionality for DE:78Q Investors
4M ago
78Q
Philogen Expands Treasury Stock as Biotech Buyback Program Advances
PremiumCompany Announcements
Philogen Expands Treasury Stock as Biotech Buyback Program Advances
4M ago
Spouse of Philogen Chairman Sells 800 Shares in Insider Transaction Disclosure
PremiumCompany Announcements
Spouse of Philogen Chairman Sells 800 Shares in Insider Transaction Disclosure
4M ago
Philogen Increases Treasury Stock with New Tranche of Share Buybacks
PremiumCompany Announcements
Philogen Increases Treasury Stock with New Tranche of Share Buybacks
4M ago
Philogen Advances Early RA Trial With F8IL10, Signaling Continued Pipeline Progress
PremiumCompany Announcements
Philogen Advances Early RA Trial With F8IL10, Signaling Continued Pipeline Progress
5M ago
78Q
Philogen Completes Early Trial of New Prostate Cancer Imaging Agent: What Investors Should Watch
PremiumCompany AnnouncementsPhilogen Completes Early Trial of New Prostate Cancer Imaging Agent: What Investors Should Watch
5M ago
78Q
Philogen’s New Phase 2 Study: A Potential Game-Changer in Skin Cancer Treatment
Premium
Company Announcements
Philogen’s New Phase 2 Study: A Potential Game-Changer in Skin Cancer Treatment
6M ago
78Q
Philogen’s New Phase 2 Study: A Potential Game-Changer in Basal Cell Carcinoma Treatment
Premium
Company Announcements
Philogen’s New Phase 2 Study: A Potential Game-Changer in Basal Cell Carcinoma Treatment
6M ago
78Q

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >